Kane Biotech Eyes Wound Care Market with Strategic Relaunch

WINNIPEG, Manitoba – February 12, 2026 – Kane Biotech Inc. has announced a significant strategic pivot, restarting commercial activities for its revyve® Antimicrobial Wound Gel product line in the United States and Canada. The move is bolstered by the appointment of two seasoned industry executives to spearhead business development, signaling a determined new push into the lucrative North American advanced wound care market.

This relaunch marks a critical juncture for the Winnipeg-based company as it aims to capitalize on a pressing medical need. The revyve® gel and spray, which have secured U.S. FDA 510(k) clearance and Health Canada approval, are designed to combat one of the most persistent challenges in wound healing: microbial biofilms.

“We are executing on our commitment to reset Kane Biotech using a disciplined market approach,” said Dr. Robert Huizinga, Interim CEO of Kane Biotech, in a statement. “We will continue to generate scientific credibility, clinical validation and with that, the commercial infrastructure.”

A Strategic Re-entry into a Growing Market

Kane Biotech is re-entering a market ripe with opportunity. The global anti-biofilm wound dressing sector was valued at over $700 million in 2022 and is projected to skyrocket to nearly $1.8 billion by 2032, driven by a compound annual growth rate of 9.7%. North America currently represents the largest share of this market, making it a critical battleground for companies with innovative solutions.

This growth is fueled by the rising prevalence of chronic wounds associated with diabetes, aging populations, and other conditions. Biofilms are a major complicating factor, implicated in an estimated 60% of all chronic wounds, where they create a barrier to healing and foster antibiotic resistance. Kane Biotech's strategy directly targets this multi-billion-dollar challenge.

However, the path forward requires navigating a cautious investor climate. The company's market capitalization stands at a modest C$7.26 million, and recent analyst ratings have been bearish, reflecting past financial performance. This commercial restart, therefore, represents not just a market expansion but a crucial effort to demonstrate value and rebuild investor confidence by turning regulatory approvals into tangible revenue streams.

The Science of Healing: Targeting Stubborn Biofilms

At the heart of Kane Biotech's strategy is the unique capability of its revyve® product line. Biofilms are complex, structured communities of microbes that adhere to surfaces, including wound beds. They secrete a protective matrix that shields them from the body's immune system and traditional antimicrobial treatments, leading to persistent infections, chronic inflammation, and delayed healing.

revyve® is engineered to disrupt this defensive shield, addressing both the biofilm structure and the underlying bacteria. By breaking down the biofilm, it allows the antimicrobial agents to work more effectively, creating a better environment for natural healing to occur. This approach offers a modern alternative in an era where antibiotic resistance is a growing global health crisis.

The company has steadily built its regulatory foundation. Following initial approvals, Kane Biotech achieved a significant milestone in July 2024 when the U.S. FDA removed a usage limitation on its wound gel, opening the door for broader application and the use of larger-volume spray formats. Furthermore, Health Canada approved the revyve® spray version in December 2025, providing Canadian clinicians with a new tool for managing large surface area wounds and burns.

Building the Commercial Engine with Veteran Leadership

Recognizing that a powerful product requires a powerful team, Kane Biotech has made two strategic appointments to drive its North American commercial efforts. Sherida (Kay) Watkins Weaver joins as Vice President of Business Development for the United States, and Patti Burke-Martin takes the same role for Canada.

These are not junior hires; they are established leaders with deep roots in the wound care industry. Kay Watkins Weaver brings over two decades of experience from leadership roles at firms like Omeza and Relevate Health, where she specialized in market access, reimbursement, and driving product adoption across complex health systems. Her expertise will be vital for navigating the intricate U.S. healthcare landscape.

Patti Burke-Martin is a recognized leader in the Canadian market, with a proven track record from senior positions at industry giants such as Coloplast and ConvaTec. Her experience in building high-performing teams and launching advanced wound care technologies across Canada is expected to be a key asset in establishing revyve® as a standard of care.

Dr. Huizinga emphasized the importance of these appointments, stating, “Kay and Patti bring deep expertise and trusted relationships in their respective markets. Their leadership will be instrumental as we expand our distribution network and support the growing adoption of revyve.”

Forging New Pathways Through Distribution

To ensure its products reach patients, Kane Biotech has established a network of non-exclusive distribution agreements. In the U.S., it has partnered with Medstream Healthcare Solutions and Patient Care Medical. While Patient Care Medical is primarily known for urological supplies, its established patient-centric distribution model and strong customer service reputation provide a ready-made channel to a segment of the patient population.

In Canada, the company has transitioned its existing agreement with Best Buy Medical Canada to a non-exclusive arrangement. This partnership is particularly significant, as Best Buy Medical is a leading national distributor with over 20 years of experience and five distribution centers ensuring rapid delivery of over 16,000 Health Canada-approved products to pharmacies, clinics, and long-term care facilities nationwide.

This non-exclusive strategy provides Kane with flexibility, allowing it to leverage the reach of established partners while also pursuing targeted sales and sampling initiatives to build brand awareness directly with clinicians. The initial shipments under these agreements, while not yet material to revenue, represent the first tangible output of the company's renewed commercial engine. As this infrastructure strengthens, the focus will be on converting scientific and clinical validation into widespread market adoption and sustained growth.